No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
No Data
Optimi Health Up 7.8% as After Health Canada Go-Ahead to Supply MDMA and Psilocybin to Patients in Australia
Optimi Health Up 12% After Reporting Drug Establishment License From Health Canada
Optimi Health to Be Sole Supplier of Psilocybin for ATMA Journey Centers Phase II Trial
Optimi Health Notes Lykos Therapeutics and FDA Priority Review of New Drug Application
Optimi Health Secures Amendment to Increase Quantities of MDMA, MDA, and 2C-B
Optimi Health Seek Regulatory Nod for Initial Testing of Psychedelic Drug Combination
No Data